Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CPG 7909 · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| CPG 7909 Injection plus chemotherapy | EXPERIMENTAL | CPG 7909 Injection plus DTIC |
| Chemotherapy alone | ACTIVE_COMPARATOR | dacarbazine |
| CPG 7909 Injection 10 mg | EXPERIMENTAL | - |
| CPG 7909 Injection 40 mg | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | Chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection |
| 2 | ACTIVE_COMPARATOR | Chemotherapy (a taxane and a platinum compound) |
| CPG 7909 Injection | EXPERIMENTAL | - |
| Cohort 1 | EXPERIMENTAL | 0.01 mg/kg CPG 7909 plus Herceptin® |
| Cohort 2 | EXPERIMENTAL | 0.04 mg/kg CPG 7909 plus Herceptin® |
| Cohort 3 | EXPERIMENTAL | 0.16 mg/kg CPG 7909 plus Herceptin® |
| Cohort 4 | EXPERIMENTAL | 0.32 mg/kg CPG 7909 plus Herceptin® |
| Name | Type | Description |
|---|---|---|
| CPG 7909 Injection | DRUG | CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly. |
| dacarbazine | DRUG | dacarbazine 850mg/m2 in three-week cycles until disease progression |
| Chemotherapy | DRUG | Chemotherapy in three-week cycles until disease progression: dacarbazine 850mg/m2 |
| CPG 7909 | DRUG | CPG 7909 Injection will be administered subcutaneously at a starting dose of 0.20 mg/kg at the beginning of Weeks 2 and 3 of the three-week cycle. |
| Herceptin® | DRUG | Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert |
Inclusion Criteria: * Histologically or cytologically confirmed melanoma that is metastatic. * Measurable disease according to the RECIST criteria. * Karnofsky Performance Status of \> 70. Exclusion Criteria: * Prior treatment with anti-neoplastic biologic or chemotherapy for recurrent or metasta...
CPG 7909 is an investigational small molecule being studied in oncology for several cancers, including metastatic breast cancer, renal cell cancer, non-small cell lung cancer, and melanoma. It is being developed by Pfizer, Inc. (PFE) and has completed clinical trials in these indications.
CPG 7909 is a small molecule immunomodulator that targets Toll-like receptor 9 (TLR9). By activating TLR9, it is designed to stimulate the immune system to recognize and attack cancer cells. This mechanism is being evaluated in multiple oncology indications.
CPG 7909 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical trials to evaluate the drug's safety and efficacy in various cancer types.
CPG 7909 is in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials in oncology indications, including non-small cell lung cancer and melanoma. The drug is investigational and has not been approved by regulatory authorities.
CPG 7909 has been studied in several completed clinical trials, including NCT00031278 in metastatic breast cancer, NCT00043407 in renal cell cancer, NCT00070629 in non-small cell lung cancer, and NCT00070642 in melanoma. These trials enrolled a total of 354 patients.
CPG 7909 is also known by the name PF-3512676. This alternative name may be used in scientific literature and clinical trial registries. Both names refer to the same investigational small molecule being developed by Pfizer for oncology indications.